Angelique Kany Kany Luabeya

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 652 citations · Full text

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Angelique Kany Kany Luabeya, Benjamin M. Kagina, Michèle Tameris et al. · Vaccine · 2015 · 190 citations

Vaccination, Pulmonary Tuberculosis, Tuberculosis Prevention +11

Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection

Elisa Nemes, Virginie Rozot, Hennie Geldenhuys et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 159 citations · Full text

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

Adam Penn‐Nicholson, Michèle Tameris, Erica Smit et al. · The Lancet Respiratory Medicine · 2018 · 146 citations

Vaccination, Vaccine Safety, Pulmonary Tuberculosis +11

Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial

Thomas J. Scriba, Andrew Fioré-Gartland, Adam Penn‐Nicholson et al. · The Lancet Infectious Diseases · 2021 · 141 citations · Full text